Anzeige
Mehr »
Dienstag, 03.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JPMY | ISIN: US64131A1051 | Ticker-Symbol: NRC
Stuttgart
02.03.26 | 21:55
1,108 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
NEURONETICS INC Chart 1 Jahr
5-Tage-Chart
NEURONETICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,1041,11607:22
1,0701,12407:16

Aktuelle News zur NEURONETICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiNeuronetics, Inc. - 8-K, Current Report1
11.02.Neuronetics Expects Q4 Revenue To Increase 86%; Stock Up21
10.02.Neuronetics, Inc. - 8-K, Current Report1
10.02.Neuronetics reports 86% revenue growth in Q4 20254
10.02.Neuronetics expects Q4 revenue of $41.8 million7
NEURONETICS Aktie jetzt für 0€ handeln
10.02.Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results162All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth...
► Artikel lesen
22.01.Neuronetics, Inc. - 8-K, Current Report5
06.01.Neuronetics, Inc. - 8-K, Current Report5
12.11.25Neuronetics: TRICARE West Expands NeuroStar TMS Coverage to Include Adolescents Aged 15+ Struggling with Depression7
04.11.25Neuronetics targets $40M-$43M Q4 revenue as SPRAVATO mix drives full-year outlook7
04.11.25Neuronetics Stock Rises 7% Despite Wider-Than-Expected Q3 Loss3
04.11.25Neuronetics reports 11% revenue growth in Q3, CEO to retire in 20265
04.11.25Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan300Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of...
► Artikel lesen
04.11.25Neuronetics, Inc. - 10-Q, Quarterly Report1
04.11.25Neuronetics, Inc. - 8-K, Current Report-
31.10.25Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)2
30.10.25Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence208MALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
► Artikel lesen
17.09.25Neuronetics: New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar Advanced Therapy, to Treat Major Depressive Disorder (MDD)12
06.08.25Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)316MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
► Artikel lesen
05.08.25Neuronetics Reports Second Quarter 2025 Financial and Operating Results512Delivered $38.1 million total revenue in the quarter, representing 18% adjusted pro forma revenue growth Generated record Greenbrook clinic revenue of $23.0 million in the quarter Reduced cash used...
► Artikel lesen
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1